伴有 PAK1/2/3 融合的肝癌:12 例系列病例。

IF 3.9 2区 医学 Q2 CELL BIOLOGY
Histopathology Pub Date : 2024-05-24 DOI:10.1111/his.15214
Thibault Kervarrec, Danna Westphal, Daniel Pissaloux, Mélanie Legrand, Franck Tirode, Anne Neuhart, Francoise Drouot, Jürgen C Becker, Nicolas Macagno, Alice Seris, Thomas Jouary, Fanny Beltzung, Marie-Laure Jullie, Paul W Harms, Bernard Cribier, Samia Mourah, Fanélie Jouenne, Gaelle Fromont, Baptiste Louveau, Maxence Mancini, Dmitry V Kazakov, Arnaud de la Fouchardière, Maxime Battistella
{"title":"伴有 PAK1/2/3 融合的肝癌:12 例系列病例。","authors":"Thibault Kervarrec,&nbsp;Danna Westphal,&nbsp;Daniel Pissaloux,&nbsp;Mélanie Legrand,&nbsp;Franck Tirode,&nbsp;Anne Neuhart,&nbsp;Francoise Drouot,&nbsp;Jürgen C Becker,&nbsp;Nicolas Macagno,&nbsp;Alice Seris,&nbsp;Thomas Jouary,&nbsp;Fanny Beltzung,&nbsp;Marie-Laure Jullie,&nbsp;Paul W Harms,&nbsp;Bernard Cribier,&nbsp;Samia Mourah,&nbsp;Fanélie Jouenne,&nbsp;Gaelle Fromont,&nbsp;Baptiste Louveau,&nbsp;Maxence Mancini,&nbsp;Dmitry V Kazakov,&nbsp;Arnaud de la Fouchardière,&nbsp;Maxime Battistella","doi":"10.1111/his.15214","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>Porocarcinoma is a malignant sweat gland tumour differentiated toward the upper part of the sweat duct and may arise from the transformation of a preexisting benign poroma. In 2019, Sekine <i>et al.</i> demonstrated the presence of <i>YAP1::MAML2</i> and <i>YAP1::NUTM1</i> fusions in most poromas and porocarcinomas. Recently, our group identified <i>PAK2-</i>fusions in a subset of benign poromas. Herein we report a series of 12 porocarcinoma cases harbouring <i>PAK1/2/3</i> fusions.</p>\n </section>\n \n <section>\n \n <h3> Methods and Results</h3>\n \n <p>Five patients were male and the median age was 79 years (ranges: 59–95). Tumours were located on the trunk (<i>n</i> = 7), on the thigh (<i>n</i> = 3), neck (<i>n</i> = 1), or groin area (<i>n</i> = 1). Four patients developed distant metastases. Microscopically, seven cases harboured a benign poroma component and a malignant invasive part. Ductal formations were observed in all, while infundibular/horn cysts and cells with vacuolated cytoplasm were detected in seven and six tumours, respectively. In three cases, the invasive component consisted of a proliferation of elongated cells, some of which formed pseudovascular spaces, whereas the others harboured a predominant solid or trabecular growth pattern. Immunohistochemical staining for CEA and EMA confirmed the presence of ducts. Focal androgen receptor expression was detected in three specimens. Whole RNA sequencing evidenced <i>LAMTOR1::PAK1</i> (<i>n</i> = 2), <i>ZDHHC5::PAK1</i> (<i>n =</i> 2), <i>DLG1::PAK2</i>, <i>CTDSP1::PAK1</i>, <i>CTNND1::PAK1</i>, <i>SSR1::PAK3</i>, <i>CTNNA1::PAK2</i>, <i>RNF13::PAK2</i>, <i>ROBO1::PAK2,</i> and <i>CD47::PAK2</i>. Activating mutation of <i>HRAS</i> (G13V, <i>n</i> = 3, G13R, <i>n</i> = 1, Q61L, <i>n</i> = 2) was present in six cases.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our study suggests that <i>PAK1/2/3</i> fusions is the oncogenic driver of a subset of porocarcinomas lacking <i>YAP1</i> rearrangement.</p>\n </section>\n </div>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/his.15214","citationCount":"0","resultStr":"{\"title\":\"Porocarcinomas with PAK1/2/3 fusions: a series of 12 cases\",\"authors\":\"Thibault Kervarrec,&nbsp;Danna Westphal,&nbsp;Daniel Pissaloux,&nbsp;Mélanie Legrand,&nbsp;Franck Tirode,&nbsp;Anne Neuhart,&nbsp;Francoise Drouot,&nbsp;Jürgen C Becker,&nbsp;Nicolas Macagno,&nbsp;Alice Seris,&nbsp;Thomas Jouary,&nbsp;Fanny Beltzung,&nbsp;Marie-Laure Jullie,&nbsp;Paul W Harms,&nbsp;Bernard Cribier,&nbsp;Samia Mourah,&nbsp;Fanélie Jouenne,&nbsp;Gaelle Fromont,&nbsp;Baptiste Louveau,&nbsp;Maxence Mancini,&nbsp;Dmitry V Kazakov,&nbsp;Arnaud de la Fouchardière,&nbsp;Maxime Battistella\",\"doi\":\"10.1111/his.15214\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>Porocarcinoma is a malignant sweat gland tumour differentiated toward the upper part of the sweat duct and may arise from the transformation of a preexisting benign poroma. In 2019, Sekine <i>et al.</i> demonstrated the presence of <i>YAP1::MAML2</i> and <i>YAP1::NUTM1</i> fusions in most poromas and porocarcinomas. Recently, our group identified <i>PAK2-</i>fusions in a subset of benign poromas. Herein we report a series of 12 porocarcinoma cases harbouring <i>PAK1/2/3</i> fusions.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods and Results</h3>\\n \\n <p>Five patients were male and the median age was 79 years (ranges: 59–95). Tumours were located on the trunk (<i>n</i> = 7), on the thigh (<i>n</i> = 3), neck (<i>n</i> = 1), or groin area (<i>n</i> = 1). Four patients developed distant metastases. Microscopically, seven cases harboured a benign poroma component and a malignant invasive part. Ductal formations were observed in all, while infundibular/horn cysts and cells with vacuolated cytoplasm were detected in seven and six tumours, respectively. In three cases, the invasive component consisted of a proliferation of elongated cells, some of which formed pseudovascular spaces, whereas the others harboured a predominant solid or trabecular growth pattern. Immunohistochemical staining for CEA and EMA confirmed the presence of ducts. Focal androgen receptor expression was detected in three specimens. Whole RNA sequencing evidenced <i>LAMTOR1::PAK1</i> (<i>n</i> = 2), <i>ZDHHC5::PAK1</i> (<i>n =</i> 2), <i>DLG1::PAK2</i>, <i>CTDSP1::PAK1</i>, <i>CTNND1::PAK1</i>, <i>SSR1::PAK3</i>, <i>CTNNA1::PAK2</i>, <i>RNF13::PAK2</i>, <i>ROBO1::PAK2,</i> and <i>CD47::PAK2</i>. Activating mutation of <i>HRAS</i> (G13V, <i>n</i> = 3, G13R, <i>n</i> = 1, Q61L, <i>n</i> = 2) was present in six cases.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Our study suggests that <i>PAK1/2/3</i> fusions is the oncogenic driver of a subset of porocarcinomas lacking <i>YAP1</i> rearrangement.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13219,\"journal\":{\"name\":\"Histopathology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-05-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/his.15214\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Histopathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/his.15214\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Histopathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/his.15214","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:孔腺癌是一种向汗腺导管上部分化的恶性汗腺肿瘤,可能由原有的良性孔腺瘤转化而来。2019 年,Sekine 等人证实大多数孔瘤和孔癌中存在 YAP1::MAML2 和 YAP1::NUTM1 融合。最近,我们的研究小组在一部分良性孔瘤中发现了 PAK2 融合。在此,我们报告了一系列12例携带PAK1/2/3融合的门静脉癌病例:五名患者为男性,中位年龄为 79 岁(59-95 岁不等)。肿瘤位于躯干(7 例)、大腿(3 例)、颈部(1 例)或腹股沟部位(1 例)。四名患者出现远处转移。从显微镜下观察,7 例患者都有良性孔瘤和恶性浸润部分。所有病例都观察到导管形成,而在七个和六个肿瘤中分别检测到内膜/角囊肿和具有空泡胞质的细胞。在三个病例中,侵袭性成分由拉长的细胞增殖组成,其中一些形成假血管间隙,而其他病例则以实性或小梁生长模式为主。CEA和EMA免疫组化染色证实了导管的存在。在三个标本中检测到局部雄激素受体表达。全RNA测序显示LAMTOR1::PAK1(n = 2)、ZDHHC5::PAK1(n = 2)、DLG1::PAK2、CTDSP1::PAK1、CTNND1::PAK1、SSR1::PAK3、CTNNA1::PAK2、RNF13::PAK2、ROBO1::PAK2和CD47::PAK2。6例患者存在HRAS激活突变(G13V,n = 3;G13R,n = 1;Q61L,n = 2):我们的研究表明,PAK1/2/3融合是缺乏YAP1重排的部分肝癌的致癌驱动因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Porocarcinomas with PAK1/2/3 fusions: a series of 12 cases

Porocarcinomas with PAK1/2/3 fusions: a series of 12 cases

Aims

Porocarcinoma is a malignant sweat gland tumour differentiated toward the upper part of the sweat duct and may arise from the transformation of a preexisting benign poroma. In 2019, Sekine et al. demonstrated the presence of YAP1::MAML2 and YAP1::NUTM1 fusions in most poromas and porocarcinomas. Recently, our group identified PAK2-fusions in a subset of benign poromas. Herein we report a series of 12 porocarcinoma cases harbouring PAK1/2/3 fusions.

Methods and Results

Five patients were male and the median age was 79 years (ranges: 59–95). Tumours were located on the trunk (n = 7), on the thigh (n = 3), neck (n = 1), or groin area (n = 1). Four patients developed distant metastases. Microscopically, seven cases harboured a benign poroma component and a malignant invasive part. Ductal formations were observed in all, while infundibular/horn cysts and cells with vacuolated cytoplasm were detected in seven and six tumours, respectively. In three cases, the invasive component consisted of a proliferation of elongated cells, some of which formed pseudovascular spaces, whereas the others harboured a predominant solid or trabecular growth pattern. Immunohistochemical staining for CEA and EMA confirmed the presence of ducts. Focal androgen receptor expression was detected in three specimens. Whole RNA sequencing evidenced LAMTOR1::PAK1 (n = 2), ZDHHC5::PAK1 (n = 2), DLG1::PAK2, CTDSP1::PAK1, CTNND1::PAK1, SSR1::PAK3, CTNNA1::PAK2, RNF13::PAK2, ROBO1::PAK2, and CD47::PAK2. Activating mutation of HRAS (G13V, n = 3, G13R, n = 1, Q61L, n = 2) was present in six cases.

Conclusion

Our study suggests that PAK1/2/3 fusions is the oncogenic driver of a subset of porocarcinomas lacking YAP1 rearrangement.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Histopathology
Histopathology 医学-病理学
CiteScore
10.20
自引率
4.70%
发文量
239
审稿时长
1 months
期刊介绍: Histopathology is an international journal intended to be of practical value to surgical and diagnostic histopathologists, and to investigators of human disease who employ histopathological methods. Our primary purpose is to publish advances in pathology, in particular those applicable to clinical practice and contributing to the better understanding of human disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信